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Available online 29 July 2016Glucocorticoids are an effective therapy for a variety of severe inﬂammatory and autoimmune disorders; howev-
er, the therapeutic use of glucocorticoids is severely limited by their negative side effects, particularly on osteo-
genesis. Glucocorticoids regulate transcription by binding to the glucocorticoid receptor (GR), which then binds
the promoters of target genes to induce either activation or repression. The gene activation effects of nuclear hor-
mone receptors broadly require the cooperation of the chromatin remodeling complex known as SWI/SNF,which
is powered by an ATPase core. The well-studied SWI/SNF ATPase, BRG1, is required for gene activation by a spec-
trum of nuclear hormone receptors including GR. However, glucocorticoid-induced side effects speciﬁcally relat-
ed to impaired osteogenesis are mostly linked with GR-mediated repression. We have considered whether cis-
repression of osteogenic genes by GR may be mediated by a distinct subclass of SWI/SNF powered by the alter-
native ATPase, BRM. BRM does not have an essential role in mammalian development, but plays a repressor
role in osteoblast differentiation and favors adipogenic lineage selection over osteoblast commitment, effects
that mirror the repressor effects of GR. The studies reported here examine three key GR cis-repression gene tar-
gets, and show that GR association with these promoters is sharply reduced in BRM deﬁcient cells. Each of these
GR-targeted genes act in a different way. Bglap encodes osteocalcin, which contributes to normal maturation of
osteoblasts from committed pre-osteoblasts. The Per3 gene product acts in uncommitted mesenchymal stem
cells to inﬂuence the osteoblast/adipocyte lineage selection point. Fas ligand, encoded by FasL, is a means by
which osteoblasts canmodulate bone degradation by osteoclasts. Repression of each of these genes by glucocor-
ticoid favors bone loss. The essential role of BRM in cooperation with GR at each of these control points offers a
novel mechanistic understanding of the role of GR in bone loss.











Mesenchymal stem cells1. Introduction
Glucocorticoids (GCs) are an effective therapy for a variety of severe
inﬂammatory and autoimmune disorders; however, the use of gluco-
corticoids at pharmacological doses is severely limited by their negative
side effects, particularly on osteogenesis (for recent reviews, see
Moutsatsou et al., 2012; Manolagas 2013; Henneicke et al., 2014;
Frenkel et al., 2015; Hartmann et al., 2016). Physiological levels ofed by the National Institute of
Health under award number
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. This is an open access article underglucocorticoids promote skeletal growth and development, but phar-
macological doses can cause osteoporosis, with fractures occurring in
30–50% of patients receiving extended GC therapy (reviewed in
Hartmann et al., 2016). Glucocorticoids affect multiple cell types that
impinge on bone formation and remodeling, but disruption of GC sig-
naling in a cell-speciﬁcmanner indicates that direct action of GCs on os-
teoblasts is the main basis for glucocorticoid-induced osteoporosis (O′
Brien et al., 2004; reviewed in Henneicke et al., 2014 and Hartmann
et al., 2016).
Glucocorticoids regulate expression of target genes by binding to the
glucocorticoid receptor (GR). Upon binding, the GR translocates from
the cytoplasm to the nucleus, where it homodimerizes and can bind to
glucocorticoid response elements (GREs) in the promoters of target
genes. Binding directly to positive GREs leads to upregulation of gene
expression, whereas binding to negative GREs (nGREs) leads to tran-
scriptional repression (reviewed in Moutsatou et al., 2012). The gluco-
corticoid receptor may also inﬂuence gene expression indirectly by
binding to other DNA-bound transcription factors. By means of thesethe CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
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the glucocorticoid receptor mediates increased transcription of anti-
inﬂammatory genes and decreased expression of pro-inﬂammatory
genes. The anti-inﬂammatory effects are believed to arise from indirect
repression of transcription factors that promote inﬂammation, as well
as direct activation of anti-inﬂammatory gene expression.
In contrast, the side effects that speciﬁcally relate to impaired differ-
entiation and maturation of osteoblasts are mostly linked with GR-
mediated repression (Moutsatsou et al., 2012). In particular, the gluco-
corticoid receptor has been shown to target nGREs directly in the pro-
moter of the osteogenic gene, Bglap (Aslam et al., 1995; Shalhoub
et al., 1998), which encodes osteocalcin, a key component of bone extra-
cellularmatrix and a physiologicalmarker of osteoblast activity. In addi-
tion, pharmacological doses of glucocorticoids favor diversion of
mesenchymal stem cells to the adipocyte lineage rather than the osteo-
blast lineage (reviewed in Henneicke et al., 2014; Hartmann et al.,
2016). This includes transactivation effects on pro-adipogenic genes,
but glucocorticoid-mediated repression plays an important role as
well by targeting inhibitors of adipogenesis. Awell-characterized exam-
ple is the Per3 gene product, which forms an inhibitory complex with
the pro-adipogenic transcription factor PPARγ, and is repressed (direct-
ly or indirectly) with glucocorticoid treatment (Costa et al., 2011).
We have considered whether cis-repression by GRmay bemediated
by a speciﬁc subclass of the SWI/SNF chromatin-remodeling complex.
Mammalian SWI/SNF is recognized as a necessary effector for the gener-
al transcription-activating effects of the nuclear hormone receptor fam-
ily including GR (King et al., 2012). The complex uses the energy of ATP
hydrolysis to remodel chromatin to permit or preclude promoter access
for various transcription-regulating factors. Mammalian SWI/SNF exists
as subclasses, powered by either of two core ATPases. One is the BRM
ATPase, which was named as an analog of the Drosophila protein, brah-
ma. The second is BRG1 (the product of BRM-related gene-1). Though
the two ATPases are closely related, their requirement in development
is very different. Mice lacking BRG1 die early in embryogenesis
(Bultman et al., 2000), while BRM-null mice are viable and fertile and
live full life spans (Reyes et al., 1998). Consequently, BRG1 has been
widely studied, and among other ﬁndings, appears to be essential for
the transcription activation effects of nuclear hormone receptors, in-
cluding the glucocorticoid receptor (Clapier and Cairns 2009,
McKenna et al., 1999). On the other hand, the involvement of SWI/SNF
in nuclear hormone receptor mediated repression has not been broadly
addressed, but evidence outlined below suggests that the BRM ATPase
may play a role in GR-mediated repression.
Despite the limited role of BRM in development, conservation of this
alternative ATPase across all higher eukaryotes argues that BRM enacts
biologically signiﬁcant functions. Evidence that BRM has an important
inﬂuence on lineage fate comes from studies of gene expression speciﬁc
to osteoblasts and adipocytes. BRM is not essential for development of
either lineage, but BRM depletion in mesenchymal stem cell precursors
impairs adipogenic gene expression and favors commitment to the os-
teoblast lineage. This manifests in BRM-null mice as resistance to age-
related osteoporosis with reduced bone marrow adiposity (Nguyen
et al., 2015). BRM depletion releases repression of key osteoblastic
genes, including the osteocalcin gene Bglap, whose promoter is occu-
pied directly by BRM-SWI/SNF prior to induction (Flowers et al.,
2009). BRM-depleted cells are unable to maintain effective co-
occupation of the Bglap promoter by repressor factors that include re-
pressor members of the E2F transcription factor family and their bind-
ing partner p130, as well as histone deacetylase-1 (HDAC1) (Flowers
et al., 2011). There is a striking correlation between the effects of BRM
and the biological effects of glucocorticoids on bone, including the evi-
dence that GR and BRM both target the osteocalcin promoter directly
to repress transactivation. Moreover, a recent ChIP-seq approach linked
BRMwith GR-mediated repression, in direct contrast to the general co-
activating role of BRG1 (Engel and Yamamoto, 2011). This analysis was
performed in tumor cells, but is likely to be more widely applicable.Given this background, we have investigated the possibility that BRM
plays a speciﬁc role in GR-mediated repression of osteogenesis.
2. Results and discussion
2.1. BRM depletion blocks glucocorticoid-mediated repression of
osteocalcin (Bglap) gene expression
The MC3T3-E1 murine calvarial cell model (Kodama et al., 1981;
Sudo et al., 1983; Kartsogiannia and Ng, 2004) was used here to assess
the role of BRM in glucocorticoid-mediated repression of gene expres-
sion. As a chromatin-remodeling complex, BRM-SWI/SNF acts directly
by promoter association. The best-characterized gene target of
glucocorticoid-mediated repression in osteoblasts is osteocalcin, a key
marker of late-stage osteoblast differentiation. Expression of the
osteocalcin-encoding gene (Bglap) is negatively affected by glucocorti-
coid treatment in vitro (Strömstedt et al., 1991). We showed previously
that induction of osteocalcin gene expression is accelerated in BRM-
deﬁcient osteoblasts (Flowers et al., 2009), raising the possibility that
glucocorticoid-mediated repression of osteocalcin expression may be
dependent on BRM. Analysis by quantitative RT-PCR (qRT-PCR) in pa-
rental cells shows typical robust induction of osteocalcin expression at
days 7 and 14 post-induction with differentiation medium (Fig. 1A).
Treatment with dexamethasone blocks induction almost completely in
the parental pre-osteoblasts. However, the BRM-depleted cells showac-
celerated induction of osteocalcin gene expression that is largely resis-
tant to the suppressive effect of dexamethasone. A parallel experiment
comparing cells depleted for the BRG1 ATPase shows BRG1 required
for normal transactivation of the osteocalcin gene as expected. Notably,
repression of the osteocalcin gene by dexamethasone remains effective
in the BRG1-depleted cells, emphasizing that repression via BRM in co-
operation with GR is distinct from the activation effect of BRG1.
2.2. BRM is required for efﬁcient GR promoter access in the regulation of
osteocalcin expression
Very little is known about speciﬁc gene targets of GR repression in
osteoblasts, butDNAseprotection assays indicateGR acts on Bglap by di-
rect cis-repression (Strömstedt et al., 1991; reviewed in Moutsatsou
et al., 2012). The osteocalcin gene is also a direct target of BRM during
repression (Flowers et al., 2009), but it is not known whether GR
targetingdepends on BRM.We addressed this question using chromatin
immunoprecipitation (ChIP) analysis (Fig. 1B). The results show that GR
targets the osteocalcin promoter directly in non-induced MC3T3-E1
pre-osteoblasts when osteocalcin expression is repressed; however, in
BRMdepleted cells incubated in the same conditions, GR is undetectable
at the promoter. The agarose gel images demonstrate the end-point PCR
products directly, and quantitative analysis conﬁrms the loss of GR and
BRM. As end-point PCR is more informative in this context, this was
used in subsequent assays.
In pre-osteoblasts, osteocalcin gene expression is normally re-
pressed, and the action of GR in Fig. 1B is supported by endogenous li-
gand. The promoter association patterns of GR and BRM were also
examined in cells induced to osteoblast differentiation in the presence
or absence of exogenous dexamethasone at pharmacological levels
(Fig. 1C). By day 14 post-induction in parental cells in the absence of
dexamethasone, GR and BRMhave both dissociated from the promoter.
In the presence of exogenous dexamethasone, GR remains on the pro-
moter at day 14 despite the differentiation-induction signals, and BRM
remains present as well, implying that BRM is recruited by GR. In cells
depleted of BRM, GR is not detected at the promoter prior to induction,
and even exogenously added dexamethasone is not sufﬁcient to estab-
lish GR at the promoter.
Because BRM-SWI/SNF acts at the level of transcription, there is a
possibility that the failure to detect GR at the promoter in BRM-
depleted cells might be caused by loss of expression of the GR-
Fig. 1. GR-mediated repression of gene targets that regulate osteoblast differentiation and commitment is dependent on BRM. A. Expression of the osteocalcin-encoding gene Bglap in
MC3T3-E1 pre-osteoblasts was assessed by qRT-PCR, normalized to expression of Gapdh. Parental MC3T3-E1 cells were induced with differentiation medium in the absence (−) or
presence (+) of the glucocorticoid, dexamethasone (Dex) for 14 days, with RNA collected at days 0, 7, and 14. MC3T3-E1-derived lines stably depleted for BRM or BRG1 were treated
in parallel. The results are presented relative to expression in non-induced (day 0) parental cells in the absence of dex. Induction of the osteocalcin gene is sharply repressed by
dexamethasone, but this effect is largely ineffective in BRM-depleted cells. BRG1-depleted cells show little induction of osteocalcin gene expression, but repression by dexamethasone
is still apparent, emphasizing that the cooperative action of BRM with glucocorticoid-mediated repression is distinct from the activation effect of BRG1. All assays were performed in
triplicate and the results are the mean of three independent trials ± SEM. B. ChIP analysis by end-point PCR and qPCR, conducted in parental and BRM-depleted MC3T3-E1 cell lines,
show the presence of BRM, BRG1, and the glucocorticoid receptor (GR) on the osteocalcin gene promoter in parental cells. In contrast, essentially no detectable DNA signal is
associated with GR when BRM is deﬁcient. C. ChIP analysis was conducted on the osteocalcin gene in parental and BRM-depleted MC3T3-E1 cells, induced to differentiate in the
absence (−) or presence (+) of dexamethasone (Dex). By day 14 post-induction in the absence of dexamethasone, GR and BRM have both dissociated from the promoter. In the
presence of exogenous dexamethasone, GR remains on the promoter at day 14 and BRM remains present as well, implying that BRM is recruited by GR. In BRM-depleted cells
exogenously added dexamethasone is not sufﬁcient to establish GR at the promoter. D. Expression of the GR-encoding gene Nr3c1 in MC3T3-E1 pre-osteoblasts was assessed by qRT-
PCR as described in Panel A. Expression is not affected by dexamethasone treatment or by depletion of BRM. E. ChIP analysis was conducted on the Per3 gene in parental and BRM-
depleted C3H10T1/2 cells. GR and BRM associate with the promoter in parental cells, but depletion of BRM shows that BRM is required to maintain detectable GR presence at the
promoter. F. Expression of Per3 in parental and BRM-depleted C3H10T1/2 cells was determined by qRT-PCR normalized to Gapdh expression. Assays were performed in triplicate and
the results of three independent trials are shown as the mean ± SEM.
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sion of Nr3c1 is not signiﬁcantly affected by depletion of BRM or by in-
duction of differentiation (Fig. 1D). Similar results were shown
previously for BRM and BRG1 (Nguyen et al., 2015). The requirement
for BRM-SWI/SNF to mediate GR access to the promoter provides a di-
rect biochemical mechanism for the gene expression results in Fig. 1A.
2.3. BRM effects are coupled with GR during lineage determination in a
mesenchymal stem cell model
BRM and glucocortocoids both play important roles in fate determi-
nation in multipotent stem cells. The C3H10T1/2 cell model of mesen-
chymal stem cells permits examination of whether the roles of GR and
BRM overlap during lineage determination, and we have previously
characterized a stable BRM-depleted derivative of this cell line
(Nguyen et al., 2015). Glucocorticoids cause mesenchymal stem cells
to favor adipogenesis over differentiation along the osteoblast lineage
(reviewed by Henneicke et al., 2014; Hartmann et al., 2016). This
often involves transactivation of adipogenic genes, but an essentialstep in advancing mesenchymal stem cells to the adipogenic fate is
glucocorticoid-mediated repression of the Per3 gene, which encodes a
strong inhibitor of adipogenesis. (Period 3 was originally classiﬁed as a
circadian rythmn gene product, but has only minimal effects on circadi-
an rhythmicity; Shearman et al., 2000). Followingmicroarray identiﬁca-
tion of Per3 as differentially expressed in C3H10T1/2 cells exposed to
glucocorticoids (So et al., 2008), moderate overexpression of Per3
(circa 5-fold) was found to potently inhibit adipocyte differentation in
mesenchymal stem cells, while Per3 knockout mice showed increased
adipogenesis (Costa et al., 2011). These authors showed further that
the Period 3 protein forms a complex with PPARγ and inhibits PPARγ-
mediated transcriptional activation. Thus, glucocorticoids repress Per3
expression, and repression of Per3 favors selection of the adipocyte lin-
eage in mesenchymal stem cells. Whether Per3 is a direct target of GR
has not yet been determined.
We used the C3H10T1/2 cell model to ask whether Per3 is a direct
target of GR and/or BRM. ChIP analysis (Fig. 1E) shows that both pro-
teins occupy the promoter, and depletion of BRM shows that BRM is re-
quired to maintain GR access to the promoter. To address whether the
Fig. 2. GR-mediated repression of gene targets that can act in trans on osteoclasts is
dependent on BRM. A. The schematic image shows the potential effect of FasL
expression by osteoblasts. Because osteoclasts express Fas ligand receptors they are
susceptible to Fas ligand-induced apoptosis. Expression of FasL by osteoblasts is a means
by which osteoblasts can signal a decrease in osteoclast numbers (Krum et al., 2004).
Repression of FasL expression could therefore increase bone resorption. Figure adapted
from http://www.iofbonehealth.org/introduction-bone-biology-all-about-our-bones
(accessed on May 31, 2016). B. Expression of FasL in MC3T3-E1 pre-osteoblasts was
assessed by qRT-PCR normalized to Gapdh expression. Parental MC3T3-E cells and the
corresponding BRM-depleted cell line were induced with differentiation medium in the
absence (−) or presence (+) of dexamethasone for 14 days. The results are presented
relative to expression in non-induced (day 0) parental cells. Normal induction of FasL
gene expression is sharply repressed by dexamethasone, but repression is ineffective in
BRM-depleted cells. Assays were performed in triplicate and the results are an average
of three independent trials, shown as the mean ± the range. C. ChIP analysis was
conducted on the FasL gene in parental and BRM-depleted MC3T3-E1 cells induced to
differentiate in the presence of dexamethasone. GR associates with the promoter in
parental cells, but depletion of BRM shows that BRM is required to maintain detectable
GR presence at the promoter. D. Parental and BRM-depleted MC3T3-E1 cell lines were
induced to differentiate in parallel for the time intervals indicated in the absence (−) or
presence (+) of dexamethasone, and stained with Alizarin Red S, which reveals the
presence of calcium-containing compounds in the cell matrix, indicative of
mineralization. The plates shown are representative of the results from three
independent induction trials.
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Per3was assessed by qRT-PCR. The results show Per3 expression elevat-
ed nearly 6-fold in the BRM depleted background (Fig. 1F), an expres-
sion level similar to that which inhibited adipocyte differentiation in
the experiments discussed above (Costa et al., 2011). In summary, glu-
cocorticoids cause mesenchymal stem cells to favor adipogenesis over
differentiation to an osteoblast phenotype (Henneicke et al., 2014;
Hartmann et al., 2016), in part by mediating repression of Per3 (Costa
et al., 2011). The current results show GR targets the Per3 promoter di-
rectly, and neither GR targeting of Per3, nor repression of Per3, is main-
tained in conditions of BRM deﬁciency.
2.4. GR promoter access to FasL and inhibition of FasL expression is BRM-
dependent
Direct action of glucocorticoids on osteoblasts appears to be the
main basis for GC-induced osteoporosis (O′Brien et al., 2004; reviewed
in Henneicke et al., 2014), but osteoblasts also have indirect effects on
osteoclasts (the cells that resorb bone). Among the signaling molecules
expressed by osteoblasts is the Fas ligand, encoded by the FasL gene.
Binding of secreted Fas ligand to receptor-bearing cells activates apo-
ptotic functions. FasL expression has mostly been studied in (activated)
T cells,where expression is strongly inhibited by glucocorticoids and the
FasL promoter is targeted directly by GR for repression (Baumann et al.,
2005; Novac et al., 2006). FasL is also expressed by osteoblasts, and be-
cause osteoclasts express Fas ligand receptors and are susceptible to Fas
ligand-induced apoptosis, expression of FasL by osteoblasts is a means
by which osteoblasts can decrease osteoclast numbers (Krum et al.,
2008). Glucocorticoid-mediated repression of FasL expression in osteo-
blasts would permit increased osteoclast numbers and excessive bone
resorption (Fig. 2A).
We examined FasL expression in differentiating MC3T3-E1 osteo-
blasts, asking whether the level of expression is affected by BRM deple-
tion (Fig. 2B). This analysis shows that FasL expression increases
dramatically during osteoblast differentiation, and that induction is
sharply inhibited when the cells are grown in the presence of dexa-
methasone. Parallel analysis in BRM-depleted cells shows robust induc-
tion of FasL expression, and strong resistance to the inhibitory effect of
dexamethasone. ChIP assays were performed to assess promoter occu-
pation (Fig. 2C). These assays show the presence of GR on the FasL pro-
moter in differentiating parental cells treated with pharmacological
levels of dexamethasone, but no detectable presence of GR on the pro-
moter in BRM-deﬁcient cells treated in parallel. Together these results
indicate that GR, in the presence of exogenous glucocorticoid signals,
acts directly in cis to inhibit expression of FasL. This disruption to a nor-
mal feedbackmechanism by which osteoblasts can potentially limit the
activity of osteoclasts is highly dependent on BRM.
2.5. BRM depletion blocks the negative effect of glucocorticoids on osteo-
blast differentiation to a mineralization phenotype
These studies identify BRM as a required factor for direct GR-
mediated cis-repression at promoters whose gene products favor osteo-
blastogenesis. GR presumably has additional direct and indirect repres-
sion targets in osteoblasts and osteoblast precursors that are not yet
known. If repression of any critical glucocorticoid target were indepen-
dent of BRM, glucocorticoids would be expected to prevent osteoblast
maturation even in BRM-deﬁcient cells. Therefore, to assess the overall
biological signiﬁcance of BRM with respect to the glucocorticoid effect
in osteoblasts we askedwhether BRM-depleted cells are able to achieve
the extracellular matrix mineralization phenotype of a mature osteo-
blast in the presence of dexamethasone. The mineralization end-point
can be detected by biological staining with Alizarin Red. This assay
(Fig. 2D) veriﬁes that dexamethasone at the pharmacological concen-
trations used here impairs progression of pre-osteoblasts to the miner-
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dexamethasone-treated cells show only weak staining even at day 28.
BRM-depleted MC3T3-E1 cells were previously shown to undergo en-
hanced mineralization (Flowers et al., 2009). Results here show that
this enhanced mineralization phenotype is maintained or even height-
ened in the presence of dexamethasone. The robustmineralization phe-
notype implies that the critical repressive effect of glucocorticoids on
osteoblast maturation are largely relieved when BRM is depleted.
2.6. Conclusions
Pharmacological levels of glucocorticoids exert their negative effects
on skeletal integrity through multiple pathways. The three direct GR
targets examined here each act in a different way. Osteocalcin functions
in normal maturation of osteoblasts from committed pre-osteoblasts.
The Per3 gene product acts in uncommitted mesenchymal stem cells
to inﬂuence the osteoblast/adipocyte lineage selection point. Fas ligand
is a means by which osteoblasts can modulate bone degradation by os-
teoclasts. Repression of these genes by glucocorticoid signals would
favor bone loss because pre-osteoblasts would not mature properly,
while fewer mesenchymal stem cells would commit to the osteoblast
lineage, and rising numbers of osteoclasts would degrade more bone.
The essential role of BRM in promoter targeting by GR at each of these
control points reveals an intimate functional association between GR-
mediated repression and BRM-SWI/SNF in osteogenesis. BRM may be
a potential therapeutic target for blocking the negative effects of gluco-
corticoids on bone. In addition, because BRM-SWI/SNF acts at the level
of chromatin remodeling, BRM deﬁciency releases multiple repressors
other thanGR fromosteogenic genes (Flowers et al., 2009, 2011) and re-
duces age-related osteoporosis (Nguyen et al., 2015), so targeting BRM
could be beneﬁcial in helping to replace bone loss in general, even sub-
sequent to glucocorticoid treatment.
3. Materials and methods
3.1. Materials
Puromycin, Alizarin Red S and dexamethasone were obtained from
Sigma Chemical Co. (St. Louis, MO); fetal bovine serum (FBS) from At-
lanta Biologicals; Trizol from Thermo Fisher (Waltham MA).
3.2. Cell lines and culture
Culture and differentiation of low passage MC3T3-E1 pre-
osteoblasts by exposure to differentiation-induction medium contain-
ing ascorbic acid and β-glycerol phosphate were described previously
(Beck et al., 2001). Generation of the MC3T3-E1-derived BRM-deleted
cell line BRM.Seq1.GG5 and the BRG1-depleted cell line BRG1.D16, as
well as staining with 0.1% Alizarin Red to reveal mineralization were
also described previously (Flowers et al., 2009). For glucocorticoid treat-
ment, cell medium was supplemented with dexamethasone at a con-
centration of 1 μM per ml; the medium was changed every 3–4 days
and supplemented with fresh dexamethasone at each change for the
duration of the experiments. Propagation of C3H10T1/2 cells and char-
acterization of the BRM-depleted line CD606 derived from the
C3H10T1/2 cell line were reported earlier (Nguyen et al., 2015).
3.3. RNA expression
RNA expression was evaluated by quantitative reverse transcription
and PCR (qRT-PCR). Each assay was performed in triplicate and the
results shown are an average of at least three independent trials.
The qRT-PCR methodology and the primers for Gapdh and Bglap
(osteocalcin) were described previously (Flowers et al., 2009). The
FasL and Nr3c1 (GR) primer sequences were designed by Origene(Rockville, MD); the Per3 primer sequences were taken from Costa
et al. (2011); the sequences are:sL Forward 5′-GAA GGA ACT GGC AGA ACT CCG T-3′
Reverse 5′-GCC ACA CTC CTC GGC TCT TTT T-3′r3c1 (GR) Forward 5′-TGG AGA GGA CAA CCT GAC TTC C-3′
Reverse 5′-ACG GAG GAG AAC TCA CAT CTG G-3′er3 Forward 5′-GTG ACA GCA GAG TCC CAT GA-3′
Reverse 5′-CAC TGC CAT CTC GAG TTC AA-3′3.4. Chromatin immunoprecipitation (ChIP) assays
ChIP assays were performed as described previously (Flowers et al.,
2014). Individual protein associations were typically analyzed at least
twice in independent experiments, and at two discrete time points in
differentiating cells. Differentiationwasmonitoredwith parallel biolog-
ical assays. Pre- and post-induction samples were always assayed in
parallel. The knockdown lines provide additional controls, particularly
for contrasting results. Quantiﬁcation was performed in triplicate on
three independent samples and normalized using the percent input
method. The following antibodies were obtained from Santa Cruz Bio-
technology: BRM (sc-6450), BRG1 (sc-10,768), and glucocorticoid re-
ceptor (sc-1002). Normal mouse IgG is a component of the EZ ChIP
system (Upstate Cell Signaling Solutions: Lake Placid, New York). The
primers for Bglap (osteocalcin) were described previously (Flowers
et al., 2009). The FasL primer sequences were taken from Baumann
et al. (2005); the sequences of the FasL and Per3 primers used here are:sL Forward 5′-CTG AAG TCA AAC CTA AGG CAG AG-3′
Reverse 5′-AGG TGC CTA ATT CAG AAG AGT TTG-3′er3 Forward 5′-TGG GAG AAA GCA GCA AGT TT-3′
Reverse 5′-AGT GGC CTG GAA GAC AAC AG-3′Potential conﬂict of interest
S. Flowers and E. Moran are authors on US Patent 8415316, whose
value could be affected by publication.
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